DelveInsight's "Graves Ophthalmopathy Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Graves Ophthalmopathy Market, historical and forecasted epidemiology, the pipeline insight as well as the Graves Ophthalmopathy market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The report provides a detailed current Graves Ophthalmopathy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
As per the study by Liaboe et al., titled “An Introductory Tutorial and Overview of Disease”, TED has a higher prevalence in women than men (16 per 100,000 vs 3 per 100,000, respectively). Both men and women demonstrate a bimodal pattern of the age of diagnosis(40–44 and 60–64 years in women; 45–49 and 65–69 years in men).
In a study conducted by Tanda ML et al. [2013], it was observed that the majority of the cases had no ocular involvement, while a larger population had mild, few had inactive GO, followed by moderate‐to‐severe and active GO, and less than 1% had sight‐threatening GO with dysthyroid optic neuropathy.
Graves Ophthalmopathy Market Trends
There are several clinical trials evaluating potential treatments for Graves Ophthalmopathy. Hence, due to increasing R&D activities, and positive results of these trials shall fuel the therapeutic market size of Graves’ ophthalmopathy.
The Graves Ophthalmopathy market analysis section of the report helps to build a detailed comprehension of the historical, current, and forecasted Graves Ophthalmopathy market trends and growth by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology. The report gives complete detail of Graves Ophthalmopathy market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Graves Ophthalmopathy Epidemiology Forecast
The Graves Ophthalmopathy epidemiology section covers insights about historical and current Graves Ophthalmopathy patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Graves Ophthalmopathy Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
The Graves Ophthalmopathy treatment option include medication (local therapy, antioxidant therapy, immunomodulatory therapy), and surgery (thyroidectomy and thyroid ablation). Worldwide some of the key market players are involved in the therapeutics development for Graves Ophthalmopathy. The therapies under development are focused on the effect of medication in patients with moderate to severe Graves Ophthalmopathy. The new therapies are expected to hit the Graves Ophthalmopathy market in the coming years. The expected launch of the therapies will impact the Graves Ophthalmopathy market growth size. Graves Ophthalmopathy Companies operating in the market include Horizon Therapeutics, Immunovant Sciences, and many others. Graves Ophthalmopathy therapies covered in the report include IMVT‐1401, Teprotumumab, and many more.
For more details, visit: Graves Ophthalmopathy Market Trends